<SEC-DOCUMENT>0001213900-24-052954.txt : 20240614
<SEC-HEADER>0001213900-24-052954.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614170003
ACCESSION NUMBER:		0001213900-24-052954
CONFORMED SUBMISSION TYPE:	AW
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		AW
		SEC ACT:		
		SEC FILE NUMBER:	333-253851
		FILM NUMBER:		241045720

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>AW
<SEQUENCE>1
<FILENAME>ea0207853-aw_therapeutics.htm
<DESCRIPTION>AMENDMENT WITHDRAWAL REQUEST
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 14, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EDGAR </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.3in"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>TherapeuticsMD, Inc. &ndash; Application for Withdrawal
of Post-Effective Amendment No. 2 to Registration Statement on Form S-3 (File No. 333-253851) </B></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reference is made to the Registration Statement on Form S-3ASR filed
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) by TherapeuticsMD, Inc. (the &ldquo;Registrant&rdquo;), on
March 4, 2021 (File No. 333-253851) (the &ldquo;2021 S-3ASR&rdquo;), the Post-Effective Amendment No. 1 to the Registration Statement
on Form S-3 (File No. 333-253851) filed with the Commission by the Registrant on March 23, 2022 (the &ldquo;2022 POSASR&rdquo;) and the
Post-Effective Amendment No. 2 to the Registration Statement on Form S-3 (File No. 333-253851) filed with the Commission by the Registrant
on March 24, 2022 (the &ldquo;2022 POS AM&rdquo; and, collectively with the 2021 S-3ASR and the 2022 POSASR, the &ldquo;Registration Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Rule 477 promulgated under the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), the Registrant hereby applies for the withdrawal solely of the 2022 POS AM, together with
all exhibits thereto, effective as of the date of this application or as soon as practicable thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2021 S-3ASR and the 2022 POSASR each became effective upon filing
with the Commission pursuant to Rule 462(e) promulgated under the Securities Act. The 2022 POS AM has not been declared effective by the
Commission. The Registrant confirms that it has not offered or sold, and has no plans to offer or sell, any securities pursuant to the
2022 POS AM. As a result, the Registrant believes that the withdrawal of the 2022 POS AM is consistent with the public interest and the
protection of investors, as contemplated by Rule 477(a) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Should you have any questions regarding the foregoing application for
withdrawal of the 2022 POS AM or if withdrawal will not be granted, please contact Joshua M. Samek of our counsel Sidley Austin LLP at
305-391-5210.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marlan Walker</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Marlan Walker</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">cc: Joshua M. Samek</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Sidley Austin LLP</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O 4H# 2(  A$! Q$!_\0
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MW\UI=M;W:^44:-]K@&50<?AFG&+DTNY,YJ*;['7<$4R26.%=TCJB^K' KF/
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M9P3],5-XQ\!MX(AAU_P_?72>3(JN78;H\\!@0!E>Q!]:[3X2'/@.W_Z[2_\
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MTN_"*]P;6.*!#T:1AQGV !/X5@^'?AY/XOME\0>*-0NY);H;XHT8 [#T))'
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ML>?H*Z2BCG?-S=1>S7)R]#F_"NARZ=X+M-'U*.-G6)HYHP=RD,S<>_!KB9/
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MZ"*(U915MT.=&,G?9GC=S\,O$4FK:;JD]Y'?7K7 FOI'DP%PRX"\<X /IV
MKTWQ)HL?B'P_>:5)(8Q.F%D SM8$,I_,"M?%%*564K7Z!"C&*:74\;TWP_\
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48+2@4&I;;-Z=*--6B.HHHJ38_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
